Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 08/26 10:00:32 pm
62.85 USD   +0.85%
08/25 INSIDE THE FDA : Frontrunners Merck & Co., Inc. (NYSE:MRK), GlaxoSm..
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitio..
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisiti..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck Combination Cholesterol Drug Fails to Meet Study Goals; Firm Doesn't Plan to Seek U.S. Approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/20/2012 | 03:17pm CEST
   By Tess Stynes 
 

Merck & Co. (>> Merck & Co., Inc.) said its doesn't plan to seek U.S. Food and Drug Administration for a combination cholesterol treatment that aims to reduce the risk of cardiovascular events after the drug failed to meet primary goals in a large long-term study.

Shares were down 2.9% at $42.40 in premarket trading.

The pharmaceutical giant said it isn't recommending that health-care providers start new patients on the treatment--Tredaptive--an extended release combination of niacin and laropiprant. The company also plans to share the study results with health regulators in countries where it also is approved under the Tredaptive or Cordaptive brands.

"While we are disappointed in these results, we thank the investigators who have conducted the study and the patients who have participated in it," said Peter S. Kim, president, Merck Research Laboratories.

The study that compared extended-release niacin and laropiprant plus statin therapy versus statin therapy included 25,673 patients in Britain, Scandinavia and China considered at risk for cardiovascular issues that were followed for a median 3.9 years.

The study found that the combination drug along with statin therapy didn't significantly further reduce the risk of a combination of cardiovascular events such as nonfatal heart attacks, strokes or coronary-related deaths compared with just statin therapy. There also was an increase in nonfatal events in the group receiving Tredaptive.

Further analysis is under way and detailed study results are expected in the first quarter.

Write to Tess Stynes at Tess.Stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
08/25 INSIDE THE FDA EBOLA EDITION : Frontrunners Merck & Co., Inc. (NYSE:MRK), GlaxoS..
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/17 DOW MOVERS : Csco, pfe
08/17 INVESTORSOBSERVER : releases covered-call reports for NVIDIA, Dicks Sporting Goo..
08/11 MERCK : Findings from Merck & Company in the Area of Medicinal Chemistry Reporte..
08/10 MERCK : Amica Mutual Insurance Co Lowers stake in Merck & Co. (MRK)
08/09DJMARKET SNAPSHOT : Stocks March Higher, Buoyed By Health-care, Consumer-staples G..
08/09 DOW MOVERS : Mrk, gs
08/09DJBotox Maker Allergan's Revenue Climbs, but Loss More Than Doubles -- WSJ
More news
Sector news : Pharmaceuticals - NEC
12:53a Stada shareholder AOC pushes through board reshuffle
12:43a ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26 MUDDY WATERS SAYS ST. JUDE SHARES CO : Cnbc
08/26DJALERE : Sues Abbott to Force Merger -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/26 A Merck Versus Bristol Showdown
08/26 Leading Real Estate Yields, Upsides, And Gains For August
08/24 Merck Offers Value, Yield, And Reliable Dividends
08/24 Candidate Clinton's harsh comments on high price of Mylan's EpiPen sends biot..
08/23 Ships And Ports Topside For Industrial Sector In August
Advertisement
Financials ($)
Sales 2016 39 681 M
EBIT 2016 13 578 M
Net income 2016 5 853 M
Debt 2016 4 707 M
Yield 2016 2,95%
P/E ratio 2016 30,51
P/E ratio 2017 20,78
EV / Sales 2016 4,50x
EV / Sales 2017 4,44x
Capitalization 173 793 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 65,5 $
Spread / Average Target 4,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.18.99%173 793
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-11.47%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-9.62%210 234
ASTRAZENECA PLC7.33%173 797
More Results